Literature DB >> 23575469

Evolution of the techniques of radiation therapy in the management of lymphoma.

Richard T Hoppe1.   

Abstract

Radiation techniques for the treatment of Hodgkin's disease have evolved dramatically in the past century. Shortly after the discovery of X-rays, the lymphomas in general, and Hodgkin's disease in particular, were noted to be radiosensitive. However, equipment limitations restricted the ability to administer sufficient doses to adequate depth to ensure long-term control. This situation improved sequentially with the development of the Coolidge tube, (60)Co machine, and medical linear accelerators. With megavoltage radiation it was possible to demonstrate cures of stage I-II disease with high-dose extended-field irradiation. When combined modality therapy programs were introduced, this permitted restriction of radiation fields and doses in order to decrease toxicity. Innovative advanced technologies such as PET simulation, 3-D treatment planning, intensity-modulated radiotherapy, active breathing control, and proton therapy have further improved the outcomes for patients treated with irradiation.

Entities:  

Mesh:

Year:  2013        PMID: 23575469     DOI: 10.1007/s10147-013-0556-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  27 in total

1.  Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study.

Authors:  Pascal Pommier; Sophie Dussart; Théodore Girinsky; Sylvie Chabaud; Jean Leon Lagrange; Tan Dat Nguyen; Véronique Beckendorff; Anne D'Hombres; Xavier Artignan; Pierre Yves Bondiau; Christian Carrie; Francesco Giammarile
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-07       Impact factor: 7.038

2.  The radical radiotherapy of regionally localized Hodgkin's disease.

Authors:  H S KAPLAN
Journal:  Radiology       Date:  1962-04       Impact factor: 11.105

3.  Hodgkin's disease: a revised clinical classification and an approach to the treatment of its localized form.

Authors:  F A BROWN; H S KAPLAN
Journal:  Stanford Med Bull       Date:  1957-08

4.  Respiratory gated beam delivery cannot facilitate margin reduction, unless combined with respiratory correlated image guidance.

Authors:  Stine S Korreman; Trine Juhler-Nøttrup; Arthur L Boyer
Journal:  Radiother Oncol       Date:  2007-11-26       Impact factor: 6.280

5.  Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.

Authors:  Bradford S Hoppe; Stella Flampouri; Zhong Su; Christopher G Morris; Naeem Latif; Nam H Dang; James Lynch; Zuofeng Li; Nancy P Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-10-17       Impact factor: 7.038

6.  Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study.

Authors:  Damien C Weber; Nicolas Peguret; Giovanna Dipasquale; Luca Cozzi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-12-01       Impact factor: 7.038

7.  On some Morbid Appearances of the Absorbent Glands and Spleen.

Authors: 
Journal:  Med Chir Trans       Date:  1832

8.  Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?

Authors:  Theodore Girinsky; Charlotte Pichenot; Anne Beaudre; Mithra Ghalibafian; Dimitri Lefkopoulos
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-19       Impact factor: 7.038

9.  Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.

Authors:  Damien C Weber; Safora Johanson; Nicolas Peguret; Luca Cozzi; Dag R Olsen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-26       Impact factor: 7.038

10.  Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.

Authors:  Andreas Engert; Petra Schiller; Andreas Josting; Richard Herrmann; Peter Koch; Markus Sieber; Friederike Boissevain; Maike De Wit; Jorg Mezger; Eckhart Duhmke; Normann Willich; Rolf-Peter Muller; Bernhard F Schmidt; Helmut Renner; Hans Konrad Muller-Hermelink; Beate Pfistner; Jurgen Wolf; Dirk Hasenclever; Markus Loffler; Volker Diehl
Journal:  J Clin Oncol       Date:  2003-08-11       Impact factor: 44.544

View more
  4 in total

1.  ISRT: a new radiation therapy for malignant lymphomas: Introduction to the review article by Specht and Yahalom.

Authors:  Keisuke Sasai; Masahiko Oguchi
Journal:  Int J Clin Oncol       Date:  2015-07-11       Impact factor: 3.402

2.  Old but new methods in radiation oncology.

Authors:  Keisuke Sasai
Journal:  Int J Clin Oncol       Date:  2013-04-24       Impact factor: 3.402

3.  Radiotherapy and Glioma Stem Cells: Searching for Chinks in Cellular Armor.

Authors:  Seamus P Caragher; Sean Sachdev; Atique Ahmed
Journal:  Curr Stem Cell Rep       Date:  2017-10-02

Review 4.  Establishment of Chimerism and Organ Transplant Tolerance in Laboratory Animals: Safety and Efficacy of Adaptation to Humans.

Authors:  Robert Lowsky; Samuel Strober
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.